Isogenica
Private Company
Total funding raised: $8.5M
Overview
Founded in 2000 and based in Cambridge, UK, Isogenica is a specialized antibody discovery company focused on VHH (single-domain) antibodies. Its core assets are massive synthetic VHH libraries and the CIS Display™ screening platform, which it uses to deliver high-affinity, developable binders for partners in a service-based model. With over 100 programmes delivered and multiple leads progressed to the clinic, Isogenica has established itself as a trusted discovery partner for biotechs and pharma, particularly in challenging target areas like membrane proteins and immuno-oncology.
Technology Platform
Proprietary synthetic VHH (single-domain antibody) libraries, described as the world's largest, combined with the CIS Display™ in vitro DNA display and screening technology for high-throughput discovery and engineering.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Isogenica competes in the antibody discovery services sector, specifically in the VHH/nanobody niche. Key competitors include other specialized discovery firms (e.g., Ablynx, now part of Sanofi, which developed the foundational nanobody platform), large CROs offering antibody services, and in-house capabilities at pharmaceutical companies. Its differentiation lies in its fully synthetic library approach and CIS Display technology.